drugset
drugset / Trial / NCT01225224

Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers

NCT01225224 ↗

Phase 1 Completed 72 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindOther

Summary

A study to evaluate the safety, tolerability and PK profiles of single and multiple doses of ASP015K in healthy nonelderly men.

Timeline

Start
2009-11-18
Primary completion
2010-03-10
Completion
2010-03-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject peficitinib Small molecule 10 mg Oral
Subject peficitinib Small molecule 20 mg Oral
Subject peficitinib Small molecule 30 mg Oral
Subject peficitinib Small molecule 60 mg Oral
Subject peficitinib Small molecule 100 mg Oral
Subject peficitinib Small molecule 200 mg Oral

Indications

No indication recorded.